Role of the vascular endohelial growth factor in bladder pain syndrome/interstitial cystitis by Ana Júlia dos Reis Pereira
  
 
 
 
 
ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR 
IN BLADDER PAIN SYNDROME/ INTERSTITIAL CYSTITIS 
 
 
 
 
ANA JÚLIA DOS REIS PEREIRA 
 
 
 
 
 
 
 
 
 
 
 
Dissertação do Mestrado em Bioquímica 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Universidade do Porto 
Faculdade de Ciências 
Instituto de Ciências Biomédicas Abel Salazar 
 
2012 
  
 
 
 
 
 
 
 
 
 
ANA JÚLIA DOS REIS PEREIRA 
 
 
 
 
 
 
ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN 
BLADDER PAIN SYNDROME/ INTERSTITIAL CYSTITIS 
 
 
 
 
 
 
 
 
 
 
 
 
Dissertação de Candidatura ao grau de 
 Mestre em Bioquímica da Universidade 
 do Porto 
 
 
 
Orientador(a): Doutora Ana Cristina Estrela de Oliveira Charrua Cordeiro 
Categoria: Bolseira de Pós-Doutoramento (Investigadora) 
Afiliação: Faculdade de Medicina da Universidade do Porto 
Co-orientador(a): Professora Doutora Célia da Conceição Duarte Cruz 
Categoria: Professora Auxiliar 
Afiliação: Faculdade de Medicina da Universidade do Porto 
 
 
 
 
 
2012
  
 
 
 
 
 
 
 
 
 
Table of Contents 
 
Table of Contents 
  
Table of Contents ............................................................................................................. 1 
List of Abbreviations and Symbols .................................................................................... 2 
Abstract ............................................................................................................................ 5 
Resumo ............................................................................................................................ 7 
Introduction ....................................................................................................................... 9 
Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) ....................................................10 
VEGF family and their receptors...................................................................................11 
VEGF molecules and their receptors in BPS/IC ............................................................13 
Materials and Methods .....................................................................................................15 
Animals ........................................................................................................................16 
Animal model ...............................................................................................................16 
Immunohistochemistry and Image acquisition ..............................................................16 
Enzyme-linked immunosorbent assay (ELISA) .............................................................17 
Creatinine Assay ..........................................................................................................18 
Statistical Analysis........................................................................................................18 
Results ............................................................................................................................19 
Expression of VEGF in the urothelium ..........................................................................20 
Expression of PlGF in the urothelium ...........................................................................21 
Expression of VEGFR1 in the urothelium .....................................................................22 
Expression of VEGF in the detrusor muscle .................................................................23 
Expression of VEGFR1 in the detrusor muscle .............................................................24 
VEGF quantification in urine .........................................................................................25 
Discussion .......................................................................................................................26 
VEGF, PlGF and VEGFR1 expression upon chronic adrenergic stimulation in the 
urothelium ....................................................................................................................27 
VEGF, PlGF and VEGFR1 expression upon chronic adrenergic stimulation in detrusor 
smooth muscle .............................................................................................................28 
VEGF quantification in urine .........................................................................................29 
Conclusions .....................................................................................................................30 
Future Prospects .............................................................................................................32 
Acknowledgements ..........................................................................................................34 
Bibliography .....................................................................................................................37 
 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
List of Abbreviations and Symbols 
  
3 
 
List of Abbreviations and Symbols 
α1- adrenergic – Alpha1-Adrenergic 
Akt/PKB – Protein Kinase B 
Bax – Bcl-2-associated X protein 
BPS/IC – Bladder Pain Syndrome/ Interstitial Cystitis 
Ca2+ – Calcium cation 2+ 
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4 
 
VEGFR3 – Vascular Endothelial Growth Factor Receptor 3 
VEGFRs – Vascular Endothelial Growth Factor Receptors 
TRPV1 – Transient Receptor Potential Cation Channel  
  
5 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
  
6 
 
Abstract 
Bladder pain syndrome/Interstitial Cystitis (BPS/IC) is characterized by suprapubic 
pain related to bladder filling, usually accompanied by urgency and nocturia, in the 
absence of urinary infection or other pathology. Recently, it has been proposed a 
hypothesis that hyperactivity of the sympathetic nervous system may be associated with 
the altered pain sensation, bladder histological changes and/or urinary frequency 
associated with BPS/IC. 
 Vascular Endothelial Growth Factor family molecules and its receptors are 
overexpressed in the bladder wall of BPS/IC patients and in animal models. In this study, 
it is hypothesized that sympathetic dysfunction, induced by chronic administration of 
phenylephrine (PHE), may result in changes in VEGF expression and function in the 
urinary bladder. 
The expression of Vascular Endothelial Growth Factor (VEGF), Placental Growth 
Factor (PlGF) and Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) in the 
urinary bladder (urothelium and detrusor muscle cells) was analysed by 
immunohistochemistry. It was observed basal expression of VEGF and PlGF in the 
urinary bladder (urothelium and detrusor muscle cells) from control animals. In PHE-
treated rats, an increase of VEGF, PlGF and VEGFR1 expression was observed in areas 
of damaged urothelium, characterized by low urothelium.  
VEGF expression and VEGFR1 in the detrusor muscle from treated rats was not 
altered, when compared to their expression in control animals. VEGF urinary levels were 
also determined by ELISA. The results obtained for concentration of VEGF in urine from 
PHE-treated rats and the one in urine from control rats were inconclusive. 
 We can speculate that VEGF and related molecules may have a relevant 
contribution to inflammatory and apoptotic events in chronic adrenergic stimulated 
animals. 
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Resumo 
O Síndrome Doloroso Vesical/ Cistite Intersticial é caracterizado por uma dor 
supra púbica relacionada com o enchimento da bexiga, normalmente acompanhada de 
frequência e nocturia, na ausência de infeção urinária ou outra patologia. Recentemente 
foi proposta a hipótese que a hiperatividade do sistema nervoso simpático possa estar 
associada com uma sensação de dor alterada, alterações histológicas na bexiga e/ ou 
aumento de frequência urinária associada à cistite intersticial. 
As moléculas da família do VEGF e os seus recetores estão sobre expressos na 
parede da bexiga dos pacientes com cistite e em modelos animais. Neste estudo, foi 
colocada a hipótese da presença de disfunção do sistema nervoso simpático induzida por 
administração crónica de fenilefrina, o que poderá resultar em alterações na expressão e 
na função do VEGF na bexiga. 
A expressão do VEGF, PlGF e VEGFR1 na bexiga (urotélio e células do músculo 
detrusor) foi então analisada por imunohistoquímica. Observou-se expressão basal do 
VEGF e PlGF na bexiga (urotélio e células do músculo detrusor) dos animais controlo. 
Nos ratos tratados com fenilefrina, um aumento da expressão de VEGF, PlGF e VEGFR1 
foi observada em áreas de urotélio degradado, caracterizado por um urotélio baixo. A 
expressão de VEGF e VEGFR1 no músculo detrusor dos animais tratados não se alterou 
em relação à expressão das mesmas nos animais controlo. 
Os níveis de VEGF na urina foram determinados por ELISA. Os resultados obtidos 
tanto para a concentração de VEGF na urina dos ratos tratados com fenilefrina e como 
para a concentração da mesma na urina dos ratos controlo foram inconclusivos. 
Pode-se especular que o VEGF e moléculas relacionadas podem ter uma 
contribuição relevante em eventos inflamatórios e apoptóticos em animais sob 
estimulação crónica adrenérgica. 
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Introduction 
Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) 
 
Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) is a chronic pathology that 
affects millions of people worldwide, being more prevalent in women with the mean age of 
40 (Lau & Bengtson, 2010). This pathology is characterized by suprapubic and pelvic pain 
related to bladder filling usually accompanied by urinary frequency (in most severe cases, 
patients can urinate between 25 to 60 times per day), urgency and nocturia, in the 
absence of urinary infection or other cause (Cheppudira et al., 2008; Temml et al., 2007). 
Thus, the common hallmark of BPS/IC is pain without a readily demonstrable pathology of 
the viscera or associated nerves (Birder et al., 2011). This has a negative impact in quality 
of life, by decreasing work productivity and sexual intimacy (Nickel et al., 2007). The 
etiology and pathophysiology of BPS/IC is not known yet (Cheppudira et al., 2008), and 
there is no reliable biological marker or effective therapy (Saban et al., 2008a). Several 
hypotheses have been proposed, such as urothelium dysfunction, a defect of the 
glycosaminoglycan layer, infection by unknown bacteria, autoimmune mechanisms and 
neurogenic inflammation (Hanno et al., 2010). Several reports demonstrate that patients 
with BPS/IC have increased levels of nitric oxide (NO), which can augment bladder wall 
permeability to water and urea, causing ultrastructural modifications in the apical layer 
(Birder et al., 2011). Furthermore, urothelial cells from BPS/IC patients present altered 
patterns of expression of cell survival and adhesion genes (Keay et al., 2012; Zhang & 
Kong, 2005). 
In addition, there is no consensus regarding the diagnostic criteria for BPS/IC. 
Patients are selected according to the perception of pelvic pain and pressure related to 
the urinary bladder (Van de Merwe et al., 2008). The exclusion of confusable diseases is 
made by analysing the past medical history, physical examination, analysis to urine and 
urine cultures, prostate-specific antigen in males above 40 years old, uroflowmetry, post-
void residual urine volume by ultrasound scanning (Van de Merwe et al., 2008). 
Hydrodystension at cystoscopy under anaesthesia and, in some cases, biopsies are also 
recommended (Van de Merwe et al., 2008). Histopathological examination of bladder 
biopsies from classic common BPS/IC patients shows extensive inflammation, and 
alterations of urothelium or bladder epithelium thinning mucosal lesions (Gamper et al., 
2009; Birder et al., 2011). Inflammation signs include detrusor mastocytosis, a mast cell 
counts exceeding 28 mast cells per mm2 (Van de Merwe et al., 2008). Mast cells may also 
play a central role in the pathogenesis and in pathophysiology of BPS/IC (Gamper et al., 
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2009). They migrate into tissue perivascular spaces, and upon activation secrete granule-
stored or de novo-synthesized molecules that mediate inflammatory reactions (Gamper et 
al., 2009). Mucosa lesions may consist of glomerulations or Hunner’s lesions (Figure 1).  
Glomerulations are characterized by bleeding at cystoscopy under hydrodistension, in 
which grade 2 is defined as large submucosal bleeding (ecchymosis) and grade 3 shows 
diffuse global mucosal bleeding (Gamper et al., 2009; van de Merwe et al., 2008). 
Hunner’s lesions are described as a distinctive inflammatory lesion showing a particular 
deep rupture through the mucosa and submucosa, caused by bladder distension (Van de 
Merwe et al., 2008). Alteration of microvessel structure, indicated by pericyte coverage, 
might be important in the formation of the glomerulations (Kiuchi et al., 2009). It is already 
known that angiogenesis and angiogenic components are important in many chronic 
inflammatory diseases. (Kiuchi et al., 2009) Actual evidence sets VEGF signaling in the 
centre of molecular pathways underlying urinary tract inflammation (Saban et al., 2008b). 
Curiously, molecules of vascular endothelial growth factor (VEGF) family are involved in 
angiogenesis control, in the recruitment of inflammatory cells and in the alteration of 
urothelium histology (Cheppudira et al., 2008; Kiuchi et al., 2009; Saban et al., 2008a)  
 
Figure 1. Classification of types of bladder pain syndrome considering analysis of the findings of cystoscopy with 
hydrodistension and of biopsies (from Van de Merwe et al., 2008; EU 53: 60) 
 
VEGF family and their receptors 
 
The VEGF family is composed by five members: Vascular Endothelial Growth 
Factor Member A (VEGFA), Vascular Endothelial Growth Factor Member B (VEGFB), 
Vascular Endothelial Growth Factor Member C (VEGFC), Vascular Endothelial Growth 
Factor Member D (VEGFD) and placental growth factor (PlGF) (Suto et al., 2005).  
The isoforms of the VEGF family with different biological activities are derived from 
the alternative splicing (Olsson et al., 2006). The human isoforms are denoted Vascular 
Endothelial Growth Factor Member A isoform 121 (VEGFA121), Vascular Endothelial 
Growth Factor Member A isoform 145 (VEGFA145), Vascular Endothelial Growth Factor 
Member A isoform 165 (VEGFA165), Vascular Endothelial Growth Factor Member A 
isoform 189 (VEGFA189) and Vascular Endothelial Growth Factor Member A isoform 206 
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(VEGFA206) (Olsson et al., 2006). The mouse isoforms are one amino-acid residue 
shorter than the corresponding human isoform, and they are denoted Vascular Endothelial 
Growth Factor Member A isoform 120 (VEGFA120) and so forth (Olsson et al., 2006). The 
bioactivity of VEGF family members can be regulated by proteolytic processing (Olsson et 
al., 2006). This event might lead to specific interactions with distinct kinds of receptors 
(Olsson et al., 2006). 
VEGFA is known for its angiogenic and potent vascular permeability-enhancing 
activity (Cheppudira et al., 2008). It supports and enhances the growth and regeneration 
of nerve fibers, with combination with other angiogenic, neurotrophic and neuroprotective 
molecules (Saban et al., 2011). In fact, dysregulation of angiogenic factors have been 
associated to neurological disorders, especially neurodegenerative pathologies (Saban et 
al., 2011).Therefore, VEGF is thought to be implicated in the cross-talk between nerves 
and vessels (Saban et al., 2011).  
PlGF is involved in pathological angiogenesis acting at different levels, such as 
directly stimulating the growth, migration and survival of endothelial cells (chemotactic 
action) leading to vessel growth and maturation, by increasing the proliferation and 
recruitment of smooth-muscle cells and supporting the proliferation of fibroblasts (De 
Falco, 2012). In addition, PlGF is essential for the recruitment and maturation of bone 
marrow-derived progenitors involved in angiogenic process  and to promote differentiation 
and activation of monocyte-macrophage lineage that are able to further support the 
angiogenic stimulus (De Falco, 2012). Therefore, it can increase vascular permeability 
and survival in vivo (De Falco, 2012). In many cases, it can act by increasing the VEGF-
induced effect, promoting the response of endothelial cells to VEGF in a cell-type-specific 
and time-dependent manner (Mac Gabhann & Popel, 2004). 
The different VEGF isoforms exert their actions upon binding the three already 
described forms of VEGF receptors: VEGF receptor 1 (VEGFR1), VEGF receptor 2 
(VEGFR2) and the rare VEGF receptor 3 (VEGFR3) (Olsson et al., 2006) (Figure 2). 
VEGF (A and B) and PlGF bind both VEGFR1, VEGFA binds VEGFR2, and VEGFC and 
VEGFD bind VEGFR3 (Mac Gabhann & Popel, 2004). VEGFR1 is involved in chemotaxis 
of inflammatory cells and a negative regulator of VEGFR2 signalling capacity (Takahashi 
& Shibuya, 2005). This negative regulation is partially accomplished through the binding of 
a VEGFR1 soluble splice variant that binds to VEGF and thereby prevents VEGF from 
binding to VEGFR2 (Olsson et al., 2006).  
VEGFR2 has a role both in normal or pathological vascular-endothelial-cell 
biology, and VEGFR3 is relevant for lymphatic-endothelial-cell development and function 
(Olsson et al., 2006).  
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Figure 2: Localization of VEGF receptors 1 and 2 homodimeric and heterodimeric structures and respective ligands 
(Olsson et al., 2006) 
 
VEGFA and its splice variants activity vary according to their different abilities to 
interact with VEGFR co-receptors (neuropilins and heparan sulphate proteoglycans) (Lee, 
et al., 2005; Woolard et al., 2004). In human bladder urothelium, mounting evidence 
suggests a clear abnormality in the distribution of VEGF-Rs and neuropilins (NRP), which 
might be important in pathophysiology and diagnosis of BPS/IC (Saban et al., 2008a). 
 
VEGF molecules and their receptors in BPS/IC 
 
VEGF expression is related to the modifications that might occur in the bladder 
vascular system (Saban et al., 2011). VEGF has a strong expression in the urothelium, as 
well as a slightest expression in endothelial cells. In lamina propria, VEGF expression is 
mild (Kiuchi et al., 2009). VEGF receptors are functionally active and localised in urothelial 
and neuronal cells in the urinary bladder, suggesting potential physiological functions of 
VEGF signalling in these cells (Saban et al., 2008b). Human umbrella cells have an 
intense expression of VEGFR1 and NRP2, contrasting with their poor expression in the 
lamina propria and the detrusor muscle (Saban et al., 2008a). In these last two layers, 
they seem confined both to blood vessels and inflammatory cells (Saban et al., 2008a). It 
has been hypothesized that the VEGF receptors expressed in non-endothelial cells are 
involved in mechanism of cell survival (Saban et al., 2008b). 
In BPS/IC some of the above mentioned proteins expression changes drastically.  
VEGF levels are increased in lamina propria and diffuse in the extracellular space of 
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BPS/IC patients that present glomerulations under hydrodistension (Kiuchi et al., 2009; 
Saban et al., 2011; Saban et al., 2008a). In addition, experiments using animal models of 
urinary bladder inflammation demonstrated that VEGF expression increases in the 
bladder wall (Saban et al., 2011). Increased expression of VEGF during cystitis is involved 
in nerve plasticity (Saban et al., 2011). In fact, VEGF induces an increase in substance P 
and TRPV1 expression, two molecules known to be expressed in urinary bladder 
nociceptors (Saban et al., 2011), indicating an additional role in the control of pain 
pathway. PlGF expression and role in BPS/IC is unknown.  
VEGFR1 and NRP2 expression is decreased during BPS/IC (Saban et al., 2008a). 
Since VEGF molecules and their receptors have a role in cell survival in normal 
conditions, it has been hypothesized that the observed changes in the expression of these 
molecules represent an additional layer of protection for urothelium (Saban et al., 2008a). 
However, if in the urothelium they present a similar role to the one observed in the control 
of vascular permeability and angiogenesis, they can be involved in urothelial leakage 
observed in BPS/IC (Saban et al., 2008a). 
Recent observations seem to indicate that there is a linkage between sympathetic 
dysfunction and VEGF molecules and their receptor activity. Overactivity of sympathetic 
nervous system may lead to degeneration of the bladder tissue, loss of bladder cells, 
angiogenesis and inflammation (Birder et al., 2011; Gamper et al., 2009; Kiuchi et al., 
2009). Increased sympathetic activity results in an increased noradrenaline release (Stein 
et al., 1999) which has apoptotic effects on urothelial cells, promote bladder inflammation 
and sensitize bladder nociceptors leading to bladder hyperactivity and increased noxious 
input (Charrua et al., 2011). In fact, increased sympathetic activity, neuron density, and 
vasomotor tone have been demonstrated in bladder tissues from patients suffering from 
BPS/IC (Stein et al., 1999).   
 
The main goal of the present work is to understand if there is a relation between 
sympathetic dysfunction and VEGF molecules and their receptors expression. In order to 
achieve this goal the bladder of chronic adrenergic stimulated rats was analysed for the 
expression of VEGF, PlGF and VEGFR1, by performing immunohistochemistry for these 
proteins and Enzyme-linked Immunoenzymatic Assay (ELISA). 
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Materials and Methods 
Animals 
 
Twelve female Wistar rats (Charles River Laboratories, Barcelona, Spain) with an 
average weight of 275g were used. Animals were maintained in the animal house at 22 ºC 
and 60% humidity under a 12-hour light-dark cycle. All experiments were performed 
according to the European Communities Council Directive of 24 November 1986 
(86/609/EEC). 
 
Animal model 
 
Animals were divided in two groups of six animals each: control group and treated 
group. Animals from control group received subcutaneous injection of saline solution and 
treated group received subcutaneous injection of 2.5 mg/Kg phenylephrine, both daily for 
14 days. At day 15, animals were anaesthetized with sodium pentobarbital 20% and the 
urine was collected to two tubes, one for each group of animals, and stored at -20ºC until 
further use. The urinary bladders were harvested and fixed in 10% formalin, overnight at 
4˚C. Then they were dehydrated, included in paraffin and sectioned at 5 µm. 
 
Immunohistochemistry and Image acquisition 
 
Bladder sections were deparaffinised and rehydrated (xylol, ethanol 100%, ethanol 
90%, ethanol 75% and distilled water, 5 minutes each). Antigen retrieval was achieved by 
heating the bladder slides immersed in 3g/L citrate buffer pH=6.0, in microwave oven, in 
maximum potency until boiling (around 7 minutes), then boiled for one minute, and then 
up to 15 minutes in the lowest potency. Slides were let in citrate buffer at room 
temperature until complete cooling. Then they were washed in 0.1 M Phosphate Buffer 
Saline (PBS) (10 minutes), and endogenous peroxidase was blocked in 1% hydroxide 
peroxide in methanol (v/v), for 10 minutes. After washing once more with 0.1 M PBS (10 
minutes), the tissue was blocked with a solution of 10% normal horse serum in 0.1 M 
Phosphate Buffer Saline + Triton X-100 (PBST). Three sections of each animal were 
incubate with each of the following primary antibody, at 4ºC, two overnights: 1:50 rabbit 
anti-VEGF (sc-152 (A-20) Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), 1:100  
goat anti-PlGF (sc-27135 (K-20), Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), 
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1:50 rabbit anti-VEGFR1 (RB-1527-P, Neomarkers, Fremont, CA). After three washes 
with 2% normal swine serum in PBST, for 10 minutes each, tissues were incubated with a 
1:200 swine anti-rabbit secondary antibody (Dako, Glostrup, Denmark) and 1:200 HRP 
conjugate donkey anti-goat (catalogue no. sc-2020, Santa Cruz Biotechnology Inc.), for 1 
hour at room temperature. The secondary antibody was washed twice with 2% normal 
swine serum in PBST, for 10 minutes, and once with PBST, for 10 minutes. Tissues were 
then treated with 1:200 horseradish peroxidase combined with biotin and avidin 
(VECTASTAIN® Elite ABC Reagent), for 1 hour, at room temperature. After washing with 
0.1 M PBS (5 minutes) and with 0.1 M Tris-HCl (5 minutes), the tissue was incubated with 
1.4 mM 3,3’-diaminobenzidine tetrahydrochloride hydrate (DAB) + 1: 4000 hydrogen 
peroxide in a 0.05 M Tris-HCl solution. DAB solution was washed with 0.1 M Tris-HCl (5 
minutes), 0.1 M PBS (5 minutes) and distilled water (5 minutes), and then counterstained 
with Hematoxylin. Bladder sections were then dehydrated (distilled water, ethanol 70%, 
ethanol 90%, ethanol 100%, xylol, each for 5 minutes) and mounted using Entellan Neu. 
All tissues were visualized with a Zeiss Vision Axioskop 40 photomicroscope and imaged 
using a AxioCam MRc5 camera driven by Axion Vision Rel 4.8 software. Immunopositive 
staining was evaluated by measuring the optical density on an arbitrary scale between 0—
white pixels and 255—black pixels in three urothelial or detrusor areas per bladder section 
with National Institutes of Health ImageJ 1.43u software. The average optical density in 
each section was then calculated. 
 
Enzyme-linked immunosorbent assay (ELISA) 
 
Enzyme-linked immunosorbent assay (ELISA) kit was used to quantify urinary 
VEGF. Urine from control (n=6) and PHE-treated rats (n=6) were assayed as described 
below, using RayBio® Rat VEGF ELISA Kit. Briefly, 96-well plates were coated with anti-
VEGF polyclonal antibodies. Urine or VEGF standards were added to each well, and 
plates were incubated. After several washes, anti-VEGF monoclonal antibodies were 
added, and plates were again incubated. After thorough washes, the amount of bound 
antibody was detected using immunoglobulin horseradish peroxidase-streptavidin 
conjugate antibody. The unbound conjugate was washed out, followed by 30 minute 
incubation with tetramethylbenzidine, at room temperature. Stop solution was added to 
terminate the reactions. Colour change was measured with a microplate reader TECAN 
infinite® 200 No. 30017581 (Mannëdorf, Switzerland) at 450 nm. All samples were run to 
duplicate, and values were averaged. VEGF levels were normalized to the urinary 
concentration of creatinine. 
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Creatinine Assay 
 
The same two pools of urine used for VEGF quantification were assayed for 
creatinine quantification, according to the specified protocol and using Creatinine (urinary) 
Assay Kit (Item No. 500701, Cayman Chemical Company, USA). Sample or Creatinine 
standard were added to the respective wells. After incubation with alkaline picrate for 10 
min, the absorbance was read at 495 nm (initial absorbance). After 20 min of incubation 
with acid solution, absorbance was read at 495 nm (final absorbance). The difference 
between the initial and the final absorbance reading of each standard, followed by the 
correction of the values subtracting the background value, generated the adjusted 
creatinine standard curve. The sample creatinine concentration was determined using the 
adjusted creatinine standard curve, previously subtracting initial and final absorbance 
readings and, to the total of this difference, subtracting the background value.  
 
Statistical Analysis 
 
Results are presented as the mean ± standard deviation. Mean differences were 
compared by one-way ANOVA, followed by the post hoc Bonferroni test for multiple 
comparisons using SigmaStat® 2.03 software with p<0.001 considered statistically 
significant. 
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Results 
Expression of VEGF in the urothelium 
 
In the current work, we aimed at observing the expression of VEGF in the 
urothelium from control and PHE-treated rats. This animal model was employed to 
characterize the influence of chronic adrenergic stimulation in the urinary bladder, more 
specifically the urothelium, considering the expression of VEGF and related molecules. An 
initial assessment of VEGF levels was performed using immunohistochemistry.  
Intensity signal of VEGF immunoreaction (VEGF-IR) in the urothelium of the 
urinary bladder of control animals was 109 +/- 47 (Figure 3A and 3D). In PHE-treated 
animals, the signal intensity of VEGF-IR was 86 +/- 61 in normal urothelium (Figure 3B 
and 3D) and  311 +/- 180 in regions with low urothelium (Figure 3C and 3D). 
 
 
 
 
 
 
       
 
 
 
 
 
   
Figure 3: Photomicrographs of VEGF expression in the urothelium of control rats (A) and in high (B) and low urothelium (C) 
from PHE 2.5 mg/Kg -treated rats. D: Mean signal intensity of VEGF expression in the urothelium of a control and in the 
normal urothelium areas (high uro) and low urothelium areas (low uro) of PHE 2.5 mg/Kg treated rats. (*** P<0.001) 
 
 
Taken together, these data showed an increase in VEGF expression in low 
urothelium from PHE-treated rats, when compared to high urothelium from PHE-treated 
and the one of control rats. 
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Expression of PlGF in the urothelium 
 
PlGF belongs to the VEGF family, and expression might be altered due to the 
chronic adrenergic stimulation. 
In this experience, we aimed at studying the expression of PlGF, in the urothelium 
from control and PHE-treated rats. PlGF levels were analysed by immunohistochemistry.  
Intensity signal of PlGF immunoreaction (PlGF-IR) in the urinary bladder of control 
animals was 45 +/- 22 (Figure 4A and 4C). In PHE-treated animals, the signal intensity of 
PlGF-IR was 64 +/- 11 in normal urothelium (Figure 4B, black arrows, and 4C) and 370 
+/- 248 in regions with low urothelium (Figure 4B, red arrow, and 4C). 
 
       
 
Figure 4: Photomicrographs of PlGF expression in the urothelium of control rats (A) and in high (B, dark arrows) and low 
urothelium (B, red arrow) from PHE 2.5 mg/Kg -treated rats. C: Mean signal intensity of PlGF expression in the urothelium of 
a control and in the normal urothelium areas (high uro) and low urothelium areas (low uro) of PHE 2.5 mg/Kg treated rats. 
(*** P<0.001) 
 
Together, these data show an augment in PlGF expression in low urothelium from 
PHE-treated rats, when compared to high urothelium of PHE-treated rats and the 
urothelium from control rats. 
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Expression of VEGFR1 in the urothelium 
 
In this experience, we intended to analyse the expression of the receptor for VEGF 
and PlGF, VEGFR1, in the urothelium from control and PHE-treated rats. VEGFR1 levels 
were determined by immunohistochemistry.  
Intensity signal of VEGFR1 immunoreaction (VEGFR1-IR) in the urinary bladder of 
control animals was 102 +/- 4 (Figure 5A and 5D). In PHE-treated animals, the signal 
intensity of VEGFR1-IR was 107 +/- 5 in normal urothelium (Figure 5B and 5D) and 128 
+/- 9 in regions with low urothelium (Figure 5B and 5D). 
 
       
         
Figure 5: Photomicrographs of VEGFR1 expression in the urothelium of control rats (A) and in high (B) and low urothelium 
(C) from PHE 2.5 mg/Kg -treated rats. D: Mean signal intensity of VEGFR1 expression in the urothelium of a control and in 
the normal urothelium areas (high uro) and low urothelium areas (low uro) of PHE 2.5 mg/Kg treated rats. (*** P<0.001) 
 
VEGFR1 expression was higher in low urothelium from PHE-treated rats, when 
compared to high urothelium of PHE-treated rats and the urothelium from control rats. 
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Expression of VEGF in the detrusor muscle 
 
In this experience, we aimed at observing the expression of VEGF in the detrusor 
smooth muscle from control and PHE-treated rats.  VEGF levels were analysed by 
immunohistochemistry.  
Intensity signal of VEGF immunoreaction (VEGF-IR) in the detrusor muscle of the 
urinary bladder of control animals was 79 +/- 9 (Figure 6A and 6C). In PHE-treated 
animals, the signal intensity of VEGF-IR was 82 +/- 10 in the detrusor muscle (Figure 6B 
and 6C). 
 
       
 
Figure 6: Photomicrographs of VEGF expression in the detrusor muscle from control (A) and PHE 2.5 mg/Kg -treated rats 
(B). C: Mean signal intensity of VEGF expression in the detrusor muscle from a control and PHE 2.5 mg/Kg treated rats. (*** 
P<0.001)
No difference was observed between detrusor from control and from PHE-treated 
rats. 
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Expression of VEGFR1 in the detrusor muscle 
 
In this experience, we intended to observe the expression of VEGFR1 in the 
detrusor smooth muscle from control and PHE-treated rats by immunohistochemistry. 
Intensity signal of VEGFR1 immunoreaction (VEGFR1-IR) in the detrusor muscle of the 
urinary bladder of control animals was 96 +/- 5 (Figure 7A and 7C). In PHE-treated 
animals, the signal intensity of VEGFR1-IR was 97 +/- 6 in the detrusor muscle (Figure 
7B and 7C). 
 
       
 
Figure 7: Photomicrographs of VEGFR1 expression in the detrusor muscle of control (A) and PHE 2.5 mg/Kg -treated rats. 
(B). C: Mean signal intensity of VEGFR1 expression in the detrusor muscle from a control and PHE 2.5 mg/Kg treated rats. 
(*** P<0.001) 
 
Taken together, these data show no difference between VEGFR1 expression 
observed in detrusor muscle from PHE-treated and from control rats. 
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VEGF quantification in urine 
 
In this experience, we intended to quantify VEGF levels in urine from control and 
PHE-treated rats recurring to ELISA. The urine of control rat presented a VEGF 
concentration of 104.0 pg/mL, creatinine value of 2265,6 nmol/mL and 0.05 pg 
VEGF/nmol creatinine. The urine from PHE-treated rats presented VEGF concentration of 
62.6 pg/mL, creatinine value of 2575.7 nmol/mL and 0.02 pg VEGF/nmol creatinine. 
 
Chart 1: Values of final concentration VEGF, creatinine and ration pg VEGF/nmol creatinine in the urine from control and 
PHE-treated rats. 
Samples 
Final concentration  
VEGF/ (pg/mL) 
creat_u/ (nmol/mL) pg VEGF/ nmol creatinine 
control 103.96 2265.58 0.05 
PHE 62.59 2575.72 0.02 
 
The value obtained for VEGF concentration in urine from PHE-treated rats and the 
one obtained in urine from control rats were inconclusive. 
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Discussion 
VEGF, PlGF and VEGFR1 expression upon chronic adrenergic 
stimulation in the urothelium 
 
In the present work we aimed to understand if there is a relation between 
sympathetic dysfunction and VEGF molecules and their receptors expression. In order to 
achieve this goal the bladder of chronic adrenergic stimulated rats was analysed for the 
expression of VEGF, PlGF and VEGFR1.  
Chronic adrenergic stimulation induced the disappearance of umbrella cells in 
some areas of the bladder. From now on these areas will be entitled of low urothelium and 
the areas with all the urothelium layers will be named high urothelium. Immunostaining 
against VEGF revealed that the high urothelium of PHE-treated rats and control animals 
had similar expression pattern. However, the low urothelium from chronic adrenergic 
treated animals had a higher expression of VEGF. This increase in the expression of 
VEGF can be related with PHE-induced mast cell migration to the mucosa (Charrua et al., 
2011). In fact, it has been shown that VEGF is involved in proliferation, migration and 
recruitment of inflammatory cells leading to persistent chronic inflammation (Cheppudira 
et al., 2008). VEGF is a chemoattractive molecule synthesized by urothelial cells 
(Cheppudira et al., 2008). In fact, VEGF binding to mast cells VEGFR1 could promote 
activation/migration of these cells, and therefore have a role in inflammation. (Cheppudira 
et al., 2008; Ciurea et al., 2011; Shibuya, 2006) 
Furthermore, it has been shown that VEGF is involved in induction of apoptosis 
(Narasimhan, et al., 2009). Overstimulation of α1 adrenergic receptor would probably lead 
to the hypertonicity of the urothelial cells, due to the constant contraction of the cells (Raz 
& Rodriguez, 2008) The levels of Ca2+, derived from the α1 adrenergic receptor activation 
by PHE, may increase in the cytosol and trigger a cascade of intracellular changes and 
activity (Luo et al., 2007). VEGFA binding to VEGFR1 may induce apoptosis through a  
PLCγ-PKC dependent mechanism  (Nishizuka, 1995; Olsson et al., 2006). This could 
explain the decrease in urothelial height and the expression of pro-apoptotic caspase 3 in 
the more external urothelial layers of PHE-treated animals (Charrua et al., 2011). VEGF 
increased levels in the urothelium, upon chronic adrenergic stimulation, reflect the 
observed in BPS/IC patients. (Kiuchi et al., 2009) 
The expression of PlGF in the urothelium of control and PHE-treated animals was 
similar to the VEGF expression. PlGF is also involved in proliferation, migration and 
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recruitment of inflammatory cells possibly leading to persistent chronic inflammation (De 
Falco, 2012). VEGF and PlGF might have a synergic effect on inflammation in the 
urothelium. In fact, it has been shown that PlGF can increase the response to VEGF in 
animal models of endothelial cell survival, migration and proliferation, acting directly or 
competing for the receptor (Mac Gabhann & Popel, 2004). 
VEGFR1 has similar expression both in urothelium from control and PHE-treated 
rats. However, overexpression of this protein was observed in low urothelium, similarly to 
what happens to its ligands. This result suggests that VEGF and PlGF may have an 
autocrine activity in urothelial cells. Hence, under chronic adrenergic stimulation, 
degradation of urothelium may upregulate VEGFR1 expression, in order to enhance the 
VEGF and PlGF effects, such as apoptotic activity (Tsao et al., 2004). 
Interestingly, VEGFR1 expression is downregulated in the urothelium from BPS/IC 
patients (Saban et al., 2008a). This difference might be explained due to the fact that 
BPS/IC bladder specimens are obtained after hydrodistension, and therefore submitted to 
mechanical stimuli (Saban et al., 2008a). 
 
VEGF, PlGF and VEGFR1 expression upon chronic adrenergic 
stimulation in detrusor smooth muscle 
 
Detrusor smooth muscle from control and PHE-treated animals expressed VEGF. 
Chronic adrenergic stimulation did not alter the expression of this molecule. This result is 
in accordance to the observed in detrusor smooth muscle of BPS/IC patients (Cheppudira 
et al., 2008; Saban et al., 2008a). In the urinary bladder of BPS/IC patients, there is a 
migration of mast cells, lymphocytes and plasma cells chemotaxis into the detrusor 
muscle (or muscularis propria) (Gamper et al., 2009; van de Merwe et al., 2008). The 
present results and the ones observed in the literature seem to indicate that this migration 
is not directly mediated by VEGF molecules (Cheppudira et al., 2008; Saban et al., 
2008a). However, in these animals, the existence of inflammatory events mediated by 
other pro-inflammatory molecules (e.g. Nerve Growth Factor (NGF), pro-inflammatory 
cytokines) cannot be excluded (Cheppudira et al., 2008). Signals may be released from 
an abnormal urothelium or penetrating through damaged urothelium and may stimulate 
submucosal and muscular nerves, leading to the recruitment and activation of 
inflammatory leukocytes, including mast cells. These mast cells will release mediators that 
will maintain inflammation. (Gamper et al., 2009) 
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VEGF quantification in urine 
 
 Urinary VEGF levels obtained for both of the pools of urine (PHE-treated rats and 
control rats) were inconclusive.   
There were only two pools of urine (urine from control rats versus urine from 
treated rats). The volume of urine collected from each rat was reduced, so two pools were 
made from each group. One solution to make the results statistically significant is to 
collect more samples of urine from a major number of rats, control and PHE-treated rats, 
and organize them in more pools. 
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Conclusions 
The present work showed that chronic treatment with phenylephrine in female rats 
caused the overexpression of VEGF, PlGF and VEGFR1 in the low bladder urothelium. 
One can hypothesize that VEGF and PlGF acting on VEGFR1 may induce urothelial 
degradation, by activating apoptotic enzymes.  
Chronic adrenergic stimulation did not induce any change in VEGF, PlGF and 
VEGFR-1 expression in the detrusor smooth muscle, suggesting that VEGF related 
molecules are not involved in direct control of detrusor activity during chronic adrenergic 
stimulation. 
The results obtained for VEGF concentration in urine from PHE-treated and control 
rats were inconclusive. A major number of samples should be assessed in order to 
understand if VEGF levels changes upon adrenergic stimulation. 
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Future Prospects 
Further approaches should be done in order to understand the true role of VEGF in 
BPS/IC. VEGF might be involved in inflammatory, angiogenic, apoptotic and chemotactic 
processes in BPS/IC. Previous studies in PHE-chronically treated rats showed the 
occurrence of apoptotic in the urothelium and bladder inflammation. The present study 
raises the hypothesis that VEGF related molecules may be involved in these mechanisms. 
Therefore, co-localization of VEGF and its related molecules and apoptotic enzymes 
should be addressed. Furthermore, experiment conduction to the confirmation of VEGF 
chemotaxis role should be addressed. 
Although chronic adrenergic stimulation does not induce any macroscopic changes 
in the urinary bladder, such as petechial appearance, angiogenesis can be addressed by 
studying pericyte migration and new vessel forming. VEGF signalling should be studied at 
a molecular level in this model in order to fully understand the apoptotic and angiogenic 
events, for instance involvement of Akt/PKB or PKC, which may explain the apoptosis, 
and relation between VEGFR1 and VEGFR2.  
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